Literature DB >> 15654354

Stem cell transplantation for patients with Fanconi anemia with low-dose cyclophosphamide and antithymocyte globulins without the use of radiation therapy.

M Ayas1, A Al-Jefri, M Al-Mahr, S Rifai, A Al-Seraihi, A Tbakhi, M Mustafa, A Khairy, E Moussa, A Iqbal, L Shalaby, H El-Solh.   

Abstract

In all, 22 patients with confirmed Fanconi anemia (FA) underwent stem cell transplantation (SCT) from HLA-matched, related donors at KFSHRC. Median age at SCT was 7.6 years (range, 2.5-14.6 years). Conditioning regimen consisted of cyclophosphamide (CY) 15 mg/kg/day intravenously (i.v.) for 4 consecutive days, in addition to equine antithymocyte globulins (ATG) given i.v. at 40 mg/kg/day for four doses pre-SCT. No radiation therapy was given. For graft-versus-host disease prophylaxis, we used cyclosporin at the standard doses; ATG was added at 20 mg/kg/dose i.v. on days 2, 4, 6, 8, 10, and 12 post-SCT (total of six doses). All patients engrafted and are alive and transfusion independent with a median follow-up time of 20.2 months (range, 3.3-59 months). One patient however developed a decrease in her WBC and platelet count. Her work-up revealed slightly hypocellular bone marrow, and a series of chimerism studies over 1 year confirmed that she has stable mixed chimerism; she remains transfusion independent. We conclude that low-dose CY without radiation therapy can be used satisfactorily in the conditioning of patients with FA undergoing related SCT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15654354     DOI: 10.1038/sj.bmt.1704787

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities.

Authors:  Jennifer E Adair; Xin Zhao; Sylvia Chien; Min Fang; Martin E Wohlfahrt; Grant D Trobridge; Jason A Taylor; Brian C Beard; Hans-Peter Kiem; Pamela S Becker
Journal:  J Mol Med (Berl)       Date:  2012-06-03       Impact factor: 4.599

2.  Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia.

Authors:  Mouhab Ayas; Wael Saber; Stella M Davies; Richard E Harris; Gregory A Hale; Gerard Socie; Jennifer LeRademacher; Monica Thakar; H Joachim J Deeg; Amal Al-Seraihy; Minoo Battiwalla; Bruce M Camitta; Richard Olsson; Rajinder S Bajwa; Carmem M Bonfim; Ricardo Pasquini; Margaret L Macmillan; Biju George; Edward A Copelan; Baldeep Wirk; Abdullah Al Jefri; Anders L Fasth; Eva C Guinan; Biljana N Horn; Victor A Lewis; Shimon Slavin; Polina Stepensky; Marc Bierings; Robert Peter Gale
Journal:  J Clin Oncol       Date:  2013-04-01       Impact factor: 44.544

3.  Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure.

Authors:  Mouhab Ayas; Mary Eapen; Jennifer Le-Rademacher; Jeanette Carreras; Hisham Abdel-Azim; Blanche P Alter; Paolo Anderlini; Minoo Battiwalla; Marc Bierings; David K Buchbinder; Carmem Bonfim; Bruce M Camitta; Anders L Fasth; Robert Peter Gale; Michelle A Lee; Troy C Lund; Kasiani C Myers; Richard F Olsson; Kristin M Page; Tim D Prestidge; Mohamed Radhi; Ami J Shah; Kirk R Schultz; Baldeep Wirk; John E Wagner; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2015-06-23       Impact factor: 5.742

Review 4.  Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation.

Authors:  Andrew C Dietz; Parinda A Mehta; Adrianna Vlachos; Sharon A Savage; Dorine Bresters; Jakub Tolar; Farid Boulad; Jean Hugues Dalle; Carmem Bonfim; Josu de la Fuente; Christine N Duncan; K Scott Baker; Michael A Pulsipher; Jeffrey M Lipton; John E Wagner; Blanche P Alter
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-20       Impact factor: 5.742

5.  Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.

Authors:  Parinda A Mehta; Stella M Davies; Thomas Leemhuis; Kasiani Myers; Nancy A Kernan; Susan E Prockop; Andromachi Scaradavou; Richard J O'Reilly; David A Williams; Leslie Lehmann; Eva Guinan; David Margolis; K Scott Baker; Adam Lane; Farid Boulad
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

6.  HLA-matched related donor hematopoietic cell transplantation in 43 patients with Fanconi anemia conditioned with 60 mg/kg of cyclophosphamide.

Authors:  Carmem M Bonfim; Carlos R de Medeiros; Marco A Bitencourt; José Zanis-Neto; Vaneuza A M Funke; Daniela C Setubal; Jefferson Ruiz; Jean E Sanders; Mary E D Flowers; Hans-Peter Kiem; Rainer Storb; Ricardo Pasquini
Journal:  Biol Blood Marrow Transplant       Date:  2007-10-18       Impact factor: 5.742

7.  Hepatotoxicity induced by horse ATG and reversed by rabbit ATG: a case report.

Authors:  Khalid A Al-Anazi; Mahmoud D Aljurf; Fahad Z Al-Sharif; Hamad M Al-Omar; Ahmed Alami; Fayyaz Farooq
Journal:  J Med Case Rep       Date:  2007-06-28

8.  Allogeneic hematopoietic stem cell transplantation for non-malignant hematological disorders.

Authors:  Hossam K Mahmoud; Alaa M Elhaddad; Omar A Fahmy; Mohamed A Samra; Raafat M Abdelfattah; Yasser H El-Nahass; Gamal M Fathy; Mohamed S Abdelhady
Journal:  J Adv Res       Date:  2014-11-07       Impact factor: 10.479

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.